期刊文献+

肿瘤坏死因子受体-抗体融合蛋白对佐剂性关节炎大鼠滑膜中TNF-α、TGF-β1和VEGF表达的影响 被引量:1

Effect of rhu-TNFR-Fc on the expression of TNF-α,TGF-β1 and VEGF in synovium of rats with adjuvant arthritis
下载PDF
导出
摘要 目的探讨肿瘤坏死因子受体-抗体融合蛋白对佐剂性关节炎大鼠滑膜中肿瘤坏死因子-α(TNF-α)、转化生长因子-β1(TGF-β1)血管内皮生长因子(VEGF)表达的影响。方法将成年雄性Wistar大鼠随机分为5组,Ⅱ~Ⅴ组建立佐剂性关节炎大鼠(AA)模型,于造模后第12天开始Ⅲ组给予甲氨喋呤灌胃治疗,Ⅳ~Ⅴ组给予益赛普皮下注射治疗。第28天取膝关节滑膜,常规HE染色,计算滑膜病理积分,免疫组织化学染色检测TNF-α、TGF-β1和VEGF在膝关节滑膜的表达。结果正常对照组大鼠滑膜组织均有少量TNF-α、TGF-β1和VEGF的表达,Ⅱ~Ⅴ组较Ⅰ组均明显增高(P<0.05)。Ⅳ、Ⅴ组滑膜组织TNF-α表达较Ⅱ组明显减低(P<0.05),而Ⅲ组与Ⅱ组无统计学意义(P>0.05)。Ⅲ~Ⅴ组滑膜组织TGF-β1、VEGF的表达均明显低于Ⅱ组,差异有统计学意义(P<0.05)。结论可溶性重组人肿瘤坏死因子受体-抗体融合蛋白可明显降低AA大鼠滑膜组织TNF-α、TGF-β1和VEGF表达,对AA大鼠的关节炎症有明显的治疗作用,可能抑制局部组织血管新生。 Objective To investigate the effect of rhu-TNFR-Fc (etanercept) on the expression of TNF-α, TGF-β1 and VEGF in synovium of rats with adjuvant arthritis (AA). Methods The adult male Wistar rats were randomly divided into 5 groups: the rats in group Ⅱ~Ⅴ were injected with Freund complete adjuvant to induce the experimental animal models with AA,on the 12th day after induction,the rats in group m were given MTX (2.7mg/kg. w) by gavage;the rats in groupiv and group V were given etanercept by subcutaneous injection. After 28 days, the synovium of joint of rats was taken out to be HE stained,then synovium pathological score was calculated, and the expression levels of TNF-α, TGF-β1 and VEGF protein in synovium of knee joint were detected by histoimmunochemistry, Results The expression levels of TNF-α,TGF-β1 and VEGF in group Ⅱ~Ⅴ were significantly higher than those in group I ( P 〈 0.05 ) , The expression levels of TNF-α in group Ⅳ and group V were obviously decreased, as compared with those in group Ⅱ ( P 〈 0.05 ), however, there were no significant differences between group m and group Ⅱ ( P 〉 0.05 ). The expression levels of TGF-β1 and VEGF in rats'synovium tissues in group Ⅲ~Ⅴ were significantly lower than those in group Ⅱ ( P 〈 0. 05 ). Conclusion Etanercept can obviously reduce the expression levels of TNF-α, TGF-β1 and VEGF in rats' synovium tissues, which has obvious therapeutic effect on joint inflammation of rats with AA. which may inhibit blood vessel neogenesis in local tissues.
出处 《河北医药》 CAS 2014年第7期969-971,共3页 Hebei Medical Journal
关键词 佐剂性关节炎大鼠 可溶性重组人肿瘤坏死因子受体一抗体融合蛋白(益赛普) 肿瘤坏死因子-α 化生长因子-β1 血管内皮生长因子 adjuvant-induce-arthritis rat rhu-TNFR-Fc tumor necrosis factor-α transforming growth factor-β1 vascular endothelial growth factor
  • 相关文献

参考文献7

  • 1Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action : A comprehensive review. Pharmacology & Thera- peutics ,2008,117 : 244-279.
  • 2张晶,左晓霞,李通,罗卉,周亚欧.沙利度胺对大鼠佐剂性关节炎的治疗作用及其对炎性细胞因子的影响[J].中华风湿病学杂志,2005,9(11):656-659. 被引量:13
  • 3Peters CL,Morris CJ,Mapp PI,et al. The Transcription Factors Hypoxia- Inducible Factor let and Ets-I Colocalize in the Hypoxic Synovium of In- flamed Joints in Adjuvant-lnduced Arthritis. Arthritis Rheanlm,2004,50: 291-296.
  • 4Baler A, Meineckel I, Gay S, et al. Apoptosis in rheumatoid ahritis. Curr Opin Rheumatol,2003,15:274-279.
  • 5Roccaro AM, Russo F, Cirulli T, el al. Antiangiogenesis for Rheumatoid Arthritis. Current Drug Targets - Inflammation Allergy,2005 ,4 :27-30.
  • 6Agarwal A,Panda S, Misra R. Effect of ctanercept on matrix metallopro- teinases and angiogenic vascular endothelial growth factor: a time kinetic study. Ann Rheum Dis,2004,63:891-892.
  • 7Paleolog EM, Young S,Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor-a and interleukin-1 in rheumatoid arthritis. Arthritis Rheum, 1998,41 : 1258-1265.

二级参考文献9

  • 1D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 1994, 91:4082-4085.
  • 2Kenyon BM, Browne F, D′Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res, 1997, 64: 971-978.
  • 3Shore A, Jaglal S, Keystone EC. Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol, 1986, 65: 293.
  • 4Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol, 1996, 14: 397.
  • 5Culy CR, Keating GM. Etanercept, updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs, 2002, 62: 2493-2537.
  • 6Sampaio EP, Samo EN, Galily R, et al. Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monocytes. J Exp Med, 1991, 173: 699-703.
  • 7Oliver SJ , Cheng TP, Banquerigo ML, et al. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol, 1998, 25: 964-969.
  • 8Fabro S, Schumacher H, Smith RL, et al. The metabolism of thalidomide: some biological effects of thalidomide and its metabolites. Br J Pharmacol, 1965, 25: 352-362.
  • 9黄烽,古洁若,赵伟,朱剑,张江林,余德恩.反应停治疗强直性脊柱炎的临床与实验研究[J].中华风湿病学杂志,2002,6(5):309-315. 被引量:75

共引文献12

同被引文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部